Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
SAN DIEGO--(BUSINESS WIRE)--May 14, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22in San Diego, California.
聖地亞哥--(美國商業資訊)--2024年5月14日-- Gossamer Bio, Inc. 納斯達克股票代碼：GOSS）是一家臨床階段的生物製藥公司，專注於開發和商業化用於治療肺動脈高壓（PH-ILD）和與間質性肺病（PH-ILD）相關的肺動脈高壓（PH-ILD）的肺動脈高壓，將在5月17日至22日舉行的美國胸科學會2024年國際會議上公佈最新的seralutinib TORREY開放標籤擴展數據在加利福尼亞州聖地亞哥。
Details for the oral presentation related to seralutinib, an inhaled, PDGFR, CSF1R and c-KIT inhibitor, designed for the treatment of pulmonary hypertension, are as follows:
與塞拉魯替尼（一種吸入式、PDGFR、CSF1R 和 C-kit 抑制劑，專爲治療肺動脈高壓而設計）相關的口頭陳述詳情如下：
Session: A14: Building Lego(Land): Lessons Learned From Large Scale Clinical Trials In PAH
Session Date & Time: Sunday, May 19th, 9:15 a.m. - 11:15 a.m. PT
Talk Title: Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Location: San Diego Convention Center, Room 29A-D (Upper Level)
Presenting Author: Olivier Sitbon, MD, PhD
會話： A14：建造樂高（樂園）：從PAH的大規模臨床試驗中吸取的經驗教訓
會話日期和時間： 5 月 19 日星期日第四，太平洋時間上午 9:15-上午 11:15
講座標題： Seralutinib治療肺動脈高壓（PAH）的1B期和2期TORREY開放標籤延期研究的中期結果
地點： 聖地亞哥會議中心，29A-D 室（上層）
主講作者： 奧利維爾·西特邦，醫學博士
Gossamer also will present additional data on seralutinib via poster. Details for those posters are as follows:
Gossamer還將通過海報展示有關塞拉替尼的更多數據。這些海報的詳細信息如下：
Poster Board Number: 424
Poster Session: D105 Balboa Park Explorers: Translational Science and Epidemiology in PH
Session Date & Time: Wednesday, May 22nd, 11:00 a.m. – 1:00 p.m. PT
Poster Title: TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve with Treatment
Location: San Diego Convention Center, Room 25A-C (Upper Level)
海報板編號： 424
海報會議： D105 巴爾博亞公園探險家：PH 中的轉化科學和流行病學
會話日期和時間： 5月22日星期三和，太平洋時間上午 11:00 — 下午 1:00
海報標題： TORREY Seralutinib 治療肺動脈高壓 (PAH) 的 2 期研究：治療後增殖、炎症和纖維化的循環生物標誌物得到改善
地點： 聖地亞哥會議中心，25A-C 會議室（上層）
Poster Board Number: 318
Poster Session: D109 Now We Got Bad Blood: RSF/PC Joint Session on Pulmonary Vascular Disease
Session Date & Time: Wednesday, May 22nd, 11:00 a.m. – 1:00 p.m. PT
Poster Title: Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates with Hemodynamics and Is Consistent with REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial
Location: San Diego Convention Center, Room 28C-E (Upper Level)
海報板編號： 318
海報會議： D109 現在我們得了壞血：RSF/PC 肺血管病聯席會議
會話日期和時間： 5月22日星期三和，太平洋時間上午 11:00 — 下午 1:00
海報標題： 在TORREY 2期PAH試驗的子研究中，心臟運動量的變化小於六分鐘的步行距離，與血液動力學相關，與REVEAL 2.0風險評分一致
地點： 聖地亞哥會議中心，28C-E 室（上層）
About Gossamer Bio
關於 Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
Gossamer Bio是一家臨床階段的生物製藥公司，專注於用於治療肺動脈高壓的血清替尼的開發和商業化。其目標是成爲肺動脈高壓的行業領導者，並改善肺動脈高壓患者的生活。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514616477/en/
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
對於投資者和媒體：
布萊恩·吉羅多，首席運營官兼首席財務官
Gossamer Bio 投資者關係
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
來源：Gossamer Bio, Inc.
譯文內容由第三人軟體翻譯。